An observational study in Rectal Cancer, sponsored by Centre Paul Strauss. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Centre Paul Strauss · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Rectal Neoplasms with a site in France — 28 open to participants now, 40 under way, 6 of them phase 3. Rectal Neoplasms · France.
Among the 160 studies in Rectal Neoplasms with a site in France, this one is the 20th largest by planned enrollment of the 27 observational ones that give a count, is one of 6 that started in 2023, is one of 27 observational ones, reaches primary completion later than 13 of the 39 other live ones, and was the 135th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →28 of the 160 studies in Rectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Medical University of Gdansk · Sites in France, Poland
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Rouen · Sites in France
Ages 18–60
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 51 · Phase 3 40 · Phase 4 2
First in 1993; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 109 across the 120 interventional studies, 100 across the 27 observational. Of the 96 that completed or were terminated, 12 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 160 have an industry lead sponsor. The 10 most frequent:
Centre Paul Strauss is the lead sponsor of 31 studies on the registry; 21 are open to participants now.
Centre Paul Strauss has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Rectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03875781Phase 3Assistance Publique - Hôpitaux de ParisNon Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer | 2026-12-05 |
| NCT06923150Qufora A/SA Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients | 2026-12 |
| NCT07000474University Hospital, BrestMultiparametric Characterization of Colorectal Cancers (METRAD) | 2026-12-31 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05933122University Hospital, LimogesStudy of the Prevalence of Sexual Dysfunction in Women After Rectal Cancer Surgery and Analysis of the Impact of a Sexologist Intervention | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 160 studies in Rectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.
The management of localized rectal cancer is done in two phases. The first phase, medical, combines a possible first chemotherapy, followed by a concomitant chemoradiotherapy. The second phase, 6 to 8 weeks later, consists of surgery of the rectum.
Magnetic resonance imaging (MRI) of the pelvis allows staging of the tumor and its possible lymph node extensions. MRI can also be used to assess tumor response after the first phase of treatment and before surgery. But MRI of the pelvis is partially imperfect.
PET-MRI is an examination that combines MRI with an injection of [18 F]fluorodeoxyglucose (18F-FDG). It is known to be more sensitive in assessing tumor stage and lymph node extensions compared to MRI and more sensitive in assessing tumor response before surgery.
The aim of this study is to determine predictive parameters for response to the first phase of treatment by accurately identifying the characteristics of tumors that have responded or not to treatment with chemotherapy and chemoradiotherapy.
Patient with histologically proven rectal cancer with an indication for induction chemotherapy followed by neoadjuvant chemoradiotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: PET-MRI
Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment. Induction chemotherapy may be performed at another center than the investigating center. After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed. A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery. A total of 4 PET MRI scans will be performed.
Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of metabolic criteria.
The purpose of this study is to determine predictive parameters for response to the first phase of treatment by accurately identifying the characteristics of tumors that have responded or not to chemotherapy and chemoradiotherapy. Metabolic criteria will be measured with the SUVmax values that will be determined on the 4 PET-MRI scans.
Time frame: At the surgery
Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of MRI criteria.
MRI criteria will be measured with the Apparent Diffusion Coefficient (ADC) values that will be determined on the 4 PET-MRI scans.
Time frame: At the surgery
Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of anatomopathological criteria.
Anatomopathological criteria will be measured with the histopathological response to treatment which will be defined according to the tumor regression grade (TRG)
Time frame: At the surgery
Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of tumor volumes
Record of tumor volumes on MRI PET 1
Time frame: At the PET MRI pretherapy (= PET MRI 1)
Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of SUVmax values
Record of SUVmax on MRI PET 1
Time frame: At the PET MRI pretherapy (= PET MRI 1)
Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of ADC values
Record of ADC on MRI PET 1
Time frame: At the PET MRI pretherapy (= PET MRI 1)
Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta tumor volume
Record of delta tumor volume, compared to baseline (PET MRI 1)
Time frame: At the 2nd PET (PET2), up to 28 months
Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta SUVmax values
Record of delta SUVmax, compared to baseline (PET MRI 1)
Time frame: At the 2nd PET (PET2), up to 28 months
Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta ADC values
Record of delta ADC, compared to baseline (PET MRI 1)
Time frame: At the 2nd PET (PET2), up to 28 months
Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta tumor volume
Record of delta tumor volume, compared to baseline (PET MRI 1)
Time frame: At the 3rd PET (PET3), up to 28 months
Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta SUVmax values
Record of delta SUVmax, compared to baseline (PET MRI 1)
Time frame: At the 3rd PET (PET3), up to 28 months
Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta ADC values
Record of delta ADC, compared to baseline (PET MRI 1)
Time frame: At the 3rd PET (PET3), up to 28 months
Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta tumor volume
Record of delta tumor volume, compared to PET3
Time frame: At the 4th PET (PET4), up to 28 months
Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta SUVmax values
Record of delta SUVmax, compared to PET3
Time frame: At the 4th PET (PET4), up to 28 months
Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta ADC values
Record of delta ADC, compared to PET3
Time frame: At the 4th PET (PET4), up to 28 months
Propose standardized criteria to differentiate responders from non-responders
Record of clinical and iconographic data predictive of good response to treatment
Time frame: Data record throughout the study, up to 28 months
Started May 2023 (actual). Primary completion is estimated for Sep 2026, 39 months after the start.
Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 39 months is below that.
Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Paul Strauss